Using large cohorts of 225,090 and 188,420 patients with Crohn’s disease or ulcerative colitis, respectively, it was demonstrated that those treated with anti-TNFα agents were less likely to develop colorectal cancer. The gene discussed is TNF; the disease is Crohn disease.